11:48 AM EDT, 09/24/2024 (MT Newswires) -- Wave Life Sciences ( WVE ) shares soared 51% in recent Tuesday trading after the company reported "positive" interim data from a phase 2 trial of WVE-N531 to treat boys with Duchenne muscular dystrophy.

Eleven boys amenable to a DMD treatment approach called exon 53 skipping were enrolled in the trial, which showed WVE-N531 was safe and well-tolerated, the company said.

"Treatment-related adverse events were mild in intensity," the company said Tuesday in a statement. "There were no serious adverse events and no study discontinuations due to any causes."

The investigational treatment also demonstrated "meaningful improvement" in metrics for muscle health, the company said.

Wave said it expects to complete the trial and receive feedback from regulators in Q1.

Price: 8.06, Change: +2.72, Percent Change: +50.94